BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
6.75
+0.03 (0.45%)
At close: Jan 22, 2026, 4:00 PM EST
6.82
+0.07 (1.04%)
After-hours: Jan 22, 2026, 7:56 PM EST
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 580 employees as of December 31, 2024. The number of employees increased by 44 or 8.21% compared to the previous year.
Employees
580
Change (1Y)
44
Growth (1Y)
8.21%
Revenue / Employee
$1,034,166
Profits / Employee
-$15,136
Market Cap
1.42B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 580 | 44 | 8.21% |
| Dec 31, 2023 | 536 | 5 | 0.94% |
| Dec 31, 2022 | 531 | 173 | 48.32% |
| Dec 31, 2021 | 358 | 112 | 45.53% |
| Dec 31, 2020 | 246 | 106 | 75.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Perrigo Company | 8,379 |
| Evotec SE | 4,740 |
| Tilray Brands | 2,842 |
| Phibro Animal Health | 2,475 |
| Amphastar Pharmaceuticals | 2,028 |
| Alvotech | 1,012 |
| ANI Pharmaceuticals | 897 |
| Dynavax Technologies | 405 |
BCRX News
- 10 days ago - BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range - GlobeNewsWire
- 16 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 weeks ago - FDA expands approval of BioCryst's rare disease drug for use in young children - Reuters
- 5 weeks ago - BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to - GlobeNewsWire
- 7 weeks ago - BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition - GlobeNewsWire
- 2 months ago - BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha